Bayer Aktiengesellschaft (BAYRY) Stock Price, News & Analysis

Company Overview

Bayer Aktiengesellschaft is a Germany-based life science company focused on health care and agriculture. Through its Pharmaceuticals, Consumer Health and Crop Science businesses, the company develops and markets products intended to improve human health, everyday self-care and agricultural productivity.

Bayer’s Pharmaceuticals business provides prescription medicines in areas such as cardiovascular disease, women’s health, oncology and specialty medicine. Its Consumer Health division offers nonprescription products in categories including pain relief, nutritional supplements, dermatology and allergy care, with brands such as Aspirin and Claritin. The Crop Science business supplies seeds, crop protection products and digital agricultural solutions for farmers and other agricultural customers.

Founded in 1863, Bayer is headquartered in Leverkusen, Germany, and serves customers in markets around the world. The company expanded its agricultural operations through the acquisition of Monsanto in 2018, adding seed and crop protection businesses to its portfolio. Bayer is led by Chief Executive Officer Bill Anderson, who assumed the role in June 2023.

Key Stats

• Today's Range: $12.27 to $12.51
• 50-Day Range: $12.07 to $14.46
• 52-Week Range: $7.48 to $15.23
• Volume: 504,391 shs
• Average Volume: 579,219 shs
• Market Capitalization: $48.46 billion
• P/E Ratio: 8.54
• Dividend Yield: 0.16%
• Price Target: N/A
• Consensus Rating: Buy

Bayer Aktiengesellschaft Stock Analysis - MarketRank™

Bayer Aktiengesellschaft scored higher than 33% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.6 / 5
• Analyst Rating: Buy

Consensus Rating

Bayer Aktiengesellschaft has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 2 strong buy ratings, 5 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Bayer Aktiengesellschaft has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 3.88%

Earnings Growth

Earnings for Bayer Aktiengesellschaft are expected to grow by 3.88% in the coming year, from $1.29 to $1.34 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Bayer Aktiengesellschaft is 8.54, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.94.

Price to Earnings Ratio vs. Sector

The P/E ratio of Bayer Aktiengesellschaft is 8.54, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 177.90.

Price to Earnings Growth Ratio

Bayer Aktiengesellschaft has a PEG Ratio of 1.82. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Bayer Aktiengesellschaft has a P/B Ratio of 1.64. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.01% of the float of Bayer Aktiengesellschaft has been sold short.

Short Interest Ratio / Days to Cover

Bayer Aktiengesellschaft has a short interest ratio ("days to cover") of 0.44, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Bayer Aktiengesellschaft has recently increased by 15.14%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.8 / 5
• Dividend Strength: Weak

Dividend Yield

Bayer Aktiengesellschaft has a dividend yield of 0.19%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Bayer Aktiengesellschaft does not have a long track record of dividend growth.

Dividend Sustainability

Based on earnings estimates, Bayer Aktiengesellschaft will have a dividend payout ratio of 1.49% next year. This indicates that Bayer Aktiengesellschaft will be able to sustain or increase its dividend.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: -0.22

News Sentiment

Bayer Aktiengesellschaft has a news sentiment score of -0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Bayer Aktiengesellschaft this week, compared to 5 articles on an average week.

Search Interest

Only 10 people have searched for BAYRY on MarketBeat in the last 30 days. This is a decrease of -23% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Bayer Aktiengesellschaft to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Bayer Aktiengesellschaft insiders have not sold or bought any company stock.

Percentage Held by Institutions

Bayer Aktiengesellschaft has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/04/2026
• Today: 10/13/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:BAYRY
• CIK: 1144145
• Web: www.bayer.com
• Phone: 49214301
• Fax: 49-21-4306-6328
• Employees: 88,078
• Year Founded: 1863

Profitability

• EPS (Trailing Twelve Months): ($0.51)
• Trailing P/E Ratio: 8.54
• Forward P/E Ratio: 9.56
• P/E Growth: 1.82
• Net Income: -$4.10 billion
• Net Margins: -3.80%
• Pretax Margin: -2.10%
• Return on Equity: 16.77%
• Return on Assets: 4.53%

Debt

• Debt-to-Equity Ratio: 1.05
• Current Ratio: 1.04
• Quick Ratio: 0.67

Sales & Book Value

• Annual Sales: $51.55 billion
• Price / Sales: 0.94
• Cash Flow: $2.21 per share
• Price / Cash Flow: 5.59
• Book Value: $7.50 per share
• Price / Book: 1.64

Miscellaneous

• Outstanding Shares: 3,930,000,000
• Free Float: N/A
• Market Cap: $48.46 billion
• Optionable: Not Optionable
• Beta: 0.57